Women's Global Health Imperative, RTI International, San Francisco, CA.
Epidemiology Division, School of Public Health, University of California, Berkeley, CA.
J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3:S222-S229. doi: 10.1097/QAI.0000000000002215.
Lower adherence to biomedical HIV prevention and challenges with persistence among young women underscore the need for methods to identify factors that will achieve higher adoption and use of effective prevention options and inform new approaches.
South Africa, Kenya, and Zimbabwe.
We synthesized findings from 2 multiphased studies (TRIO and Quatro) conducted with young women aged 18-30 years that included a crossover clinical study with placebo products, a discrete-choice experiment, and qualitative interviews with women, male partners, and health providers. TRIO evaluated 3 products (tablets, ring, and injections), and Quatro compared 4 vaginal products (ring, insert, film, and gel) for HIV prevention. Both were designed to assess product preferences, choice, and use.
Increased experience with placebo products in the crossover study informed young women's product ratings and preferences. Over half changed their mind regarding their most preferred product after trying each one. The integrated qualitative component was vital to understanding what prompted these preference shifts. The discrete choice experiment provided insights on how features not available in placebos, like efficacy and contraception, influence choice and the tradeoffs women may be willing to make to gain a desired product feature.
The use of multiple research methods allowed for evaluation of varied dimensions of acceptability, preference, and choice in the context of diverse biomedical HIV prevention delivery forms. Findings elucidated the value of product choice with differences in preference within and across settings. Collectively, the 3 methodologies offered important insights about these products informative to enhanced product design development and future implementation.
年轻女性对生物医学艾滋病毒预防措施的依从性较低，且持续存在困难，这突显了需要找到能够提高有效预防措施的采用和使用的因素，为新方法提供信息。
南非、肯尼亚和津巴布韦。
我们综合了两项多阶段研究（TRIO 和 Quatro）的研究结果，这些研究是针对年龄在 18-30 岁的年轻女性进行的，其中包括使用安慰剂产品的交叉临床研究、离散选择实验以及对女性、男性伴侣和卫生保健提供者的定性访谈。TRIO 评估了 3 种产品（片剂、环和注射剂），Quatro 比较了 4 种阴道产品（环、插入物、薄膜和凝胶）在预防艾滋病毒方面的效果。这两项研究旨在评估产品偏好、选择和使用。
在交叉研究中，对安慰剂产品的更多体验使年轻女性对产品的评价和偏好发生了变化。超过一半的女性在尝试了每种产品后改变了对最喜爱产品的看法。综合的定性部分对于理解是什么促使了这些偏好的转变至关重要。离散选择实验提供了有关影响选择的因素的见解，这些因素是在安慰剂中不可用的，如功效和避孕，以及女性为获得所需产品特性而可能愿意做出的权衡。
使用多种研究方法可以在不同的生物医学艾滋病毒预防措施提供形式的背景下，评估可接受性、偏好和选择的不同维度。研究结果阐明了在不同环境中偏好存在差异的情况下，产品选择的价值。总的来说，这三种方法提供了关于这些产品的重要见解，这些见解有助于增强产品设计的开发和未来的实施。
